The effect of proactive therapy with tacrolimus and betamethasone butyrate on atopic dermatitis: Randomized placebo-controlled study

The effect of proactive therapy with tacrolimus and betamethasone butyrate on atopic dermatitis: Randomized placebo-controlled study - The effect of proactive therapy on atopic dermatitis: Randomized placebo-controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006955

Enrollment

Registered

2011-12-26

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

group 1:tacrolimus group 2: betamethasone butyrate group 3: vaceline(placebo)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult (>20 years old) patients with atopic dermatitis with agreement to this sudy

Exclusion criteria

Exclusion criteria: 1. Cases who are discouraged to use tacrolimus or steroid ointment. 2. Cases with intorelance to these ointment. 3. pregnant woman 4. cases who are judged to discourage by attending physician.

Design outcomes

Primary

Measure	Time frame
a. SCORAD (severity score) b. investigator's global assessment c. safety (comparing between tacrolimus and steroid ointment) d. serum cortisol e. serum TARC f. DLQI (QoL) g. intensity of itch h. history of usage of external medicine i. adverse/side effect j. length of remission	—

Countries

Japan

Contacts

Public Contact0668795111

Osaka university Dermatology

h-murota@derma.med.osaka-u.ac.jp0668795111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026